Denali Therapeutics's market cap is currently €2.97B. The company's EPS TTM is €-2.552; its P/E ratio is ―; Denali Therapeutics is scheduled to report earnings on March 3, 2025, and the estimated EPS forecast is €-0.76. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 330.53M	$ 108.46M	$ 48.66M	$ 335.66M	$ 26.68M
Gross Profit	$ 313.81M	$ 101.43M	$ 43.05M	$ 123.04M	$ -166.70M
Operating Income	$ -196.70M	$ -340.74M	$ -295.75M	$ 62.72M	$ -213.18M
EBITDA	$ -179.97M	$ -330.36M	$ -287.16M	$ 62.72M	$ -205.19M
Net Income	$ -145.22M	$ -325.99M	$ -290.58M	$ 71.14M	$ -197.61M
Balance Sheet
Cash & Short-Term Investments	$ 1.03B	$ 1.34B	$ 865.41M	$ 1.47B	$ 415.36M
Total Assets	$ 1.15B	$ 1.46B	$ 1.40B	$ 1.60B	$ 553.23M
Total Debt	$ 52.24M	$ 60.35M	$ 58.55M	$ 64.17M	$ 68.86M
Net Debt	$ -74.86M	$ -157.69M	$ -234.92M	$ -442.97M	$ -10.58M
Total Liabilities	$ 122.96M	$ 417.81M	$ 441.87M	$ 453.75M	$ 158.34M
Stockholders' Equity	$ 1.03B	$ 1.04B	$ 962.29M	$ 1.15B	$ 394.89M
Cash Flow
Free Cash Flow	$ -370.93M	$ -262.55M	$ -219.89M	$ 413.06M	$ -169.50M
Operating Cash Flow	$ -357.99M	$ -244.72M	$ -211.39M	$ 416.15M	$ -151.58M
Investing Cash Flow	$ 249.31M	$ -141.39M	$ -21.63M	$ -623.21M	$ 147.71M
Financing Cash Flow	$ 17.82M	$ 310.67M	$ 19.35M	$ 634.75M	$ 6.19M

Currency in USD

Denali Therapeutics Earnings and Revenue History

Income Statement >

Denali Therapeutics Debt to Assets

Balance Sheet >

Denali Therapeutics Cash Flow

Cash Flow >

Denali Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing